Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)94.82
  • Today's Change2.09 / 2.25%
  • Shares traded4.10m
  • 1 Year change12.99%
  • Beta0.9592
Data delayed at least 15 minutes, as of Jul 14 2020 21:10 BST.
More ▼

Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

  • Revenue in USD (TTM)32.10bn
  • Net income in USD3.55bn
  • Incorporated1900
  • Employees107.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttps://www.abbott.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DexCom, Inc.1.60bn147.90m38.12bn3.90k253.8439.93190.8823.811.591.5917.2910.120.72394.646.33410,410.306.69-1.967.70-2.3164.7865.659.24-2.245.415.600.5376--43.0841.61179.29--61.86--
Edwards Lifesciences Corp4.48bn1.11bn41.64bn13.90k38.4910.6734.599.291.751.747.056.300.77671.787.71322,568.3019.2415.1921.8818.1174.4074.3924.7721.992.47--0.13230.0016.7913.3642.245.2924.33--
Baxter International Inc11.53bn797.00m42.47bn50.00k54.625.5126.613.681.531.9122.3715.140.65273.866.24230,520.004.589.525.5811.9942.4142.297.0116.392.1915.820.45824.492.371.17-40.0012.04-18.18-16.14
Boston Scientific Corporation10.79bn185.00m49.20bn36.00k262.243.4939.554.560.13133.037.649.860.40012.286.74299,583.300.68263.270.80954.1369.8470.791.717.200.80362.830.42820.009.287.78-62.72--16.44--
Intuitive Surgical, Inc.4.60bn1.39bn66.62bn7.33k49.267.8340.7914.4711.6011.6038.5172.960.50802.628.56628,487.6015.3815.1417.0016.9269.0469.3030.2829.354.30--0.000.0020.2516.0122.2426.9232.15--
Stryker Corporation14.96bn2.16bn66.76bn40.00k31.235.0922.634.465.705.7039.3734.940.54021.606.07373,900.007.828.219.119.9765.7366.2314.4714.501.77--0.444836.529.439.004.4632.2422.7411.26
Becton Dickinson and Co17.41bn853.00m74.59bn70.09k82.933.3424.504.283.103.3663.3277.090.32823.447.85248,412.801.892.792.223.2246.4747.275.767.200.65815.500.502672.798.1815.4129.16-2.737.947.16
Medtronic PLC28.91bn4.73bn124.43bn90.00k26.532.4516.804.303.503.5421.4037.830.32062.325.32321,255.605.264.665.885.2167.9469.0616.4015.101.7213.130.327756.43-5.387.371.7912.0616.2612.10
Thermo Fisher Scientific Inc.25.65bn3.70bn149.66bn75.00k41.265.2424.975.849.189.1163.7272.310.44884.345.50341,960.006.475.277.195.9444.3045.0314.4112.441.6910.740.41159.804.868.6221.2414.3416.714.28
Abbott Laboratories32.10bn3.55bn164.66bn107.00k46.725.4524.805.131.992.0118.0117.080.47773.086.03299,953.305.283.966.234.6858.4757.2211.068.811.018.440.375280.964.349.5246.1415.918.757.30
Data as of Jul 14 2020. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

33.70%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2020147.23m8.32%
Capital Research & Management Co. (Global Investors)as of 31 Mar 202095.87m5.42%
BlackRock Fund Advisorsas of 31 Mar 202084.27m4.76%
SSgA Funds Management, Inc.as of 31 Mar 202074.08m4.19%
Capital Research & Management Co. (International Investors)as of 31 Mar 202055.78m3.15%
Wellington Management Co. LLPas of 31 Mar 202043.18m2.44%
Massachusetts Financial Services Co.as of 31 Mar 202027.37m1.55%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202026.79m1.52%
Geode Capital Management LLCas of 31 Mar 202024.85m1.41%
Polen Capital Management LLCas of 31 Mar 202016.66m0.94%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.